• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" Vaccine 41(1) (2023) 85-91
Vaccine. 2023 Aug 23:S0264-410X(23)00870-8. doi: 10.1016/j.vaccine.2023.07.039. Online ahead of print.NO ABSTRACTPMID:37625991 | DOI:10.1016/j.vaccine.2023.07.039
Source: Vaccine - August 25, 2023 Category: Allergy & Immunology Authors: Nusrat Homaira Roxanne Strachan Helen Quinn Sean Beggs Mejbah Bhuiyan Asha Bowen Laura K Fawcett Gwendolyn L Gilbert Stephen B Lambert Kristine Macartney Helen S Marshall Andrew C Martin Gabrielle McCallum Angela McCullagh Tim McDonald Hiran Selvadurai Pe Source Type: research

Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5  years in Shanghai, China: An observational study
CONCLUSIONS: PCV13 vaccination among children aged 0-5 years substantially reduced the incidence of all-cause pneumonia. Direct immunization of children under 5 years is an effective strategy to combat outpatient pneumonia, and hospitalized pneumonia.PMID:37620204 | DOI:10.1016/j.vaccine.2023.08.041
Source: Vaccine - August 24, 2023 Category: Allergy & Immunology Authors: Jie Tian Bo Zheng Laibao Yang Ying Guan Chunze Xu Weibing Wang Source Type: research

Timeliness of childhood vaccination in England: A population-based cohort study
We described vaccine uptake for representative antigens (pertussis, pneumococcus, measles) by age in days and stratified by ethnicity, region and birth cohort. Alluvial diagrams were used to illustrate common journeys through the vaccination schedule, and we applied survival analysis using accelerated failure time models (AFT) to predict age of vaccine receipt based on timing of previous doses.RESULTS: 573,015 children were followed up until their fifth birthday, when they had 90.16 % coverage for two doses of measles, mumps, rubella (MMR) vaccine and 88.78% coverage for four doses of diphtheria, tetanus, pertussis (DTP) v...
Source: Vaccine - August 13, 2023 Category: Allergy & Immunology Authors: Anne M Suffel Jemma L Walker Elizabeth Williamson Helen I McDonald Charlotte Warren-Gash Source Type: research

Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies
CONCLUSIONS: Vaccinating older adults with higher-valency PCVs, especially PCV20, could substantially reduce the remaining IPD burden in high-income countries, regardless of current PCV use in pediatric NIPs and adult PPSV23 policies.PMID:37544825 | DOI:10.1016/j.vaccine.2023.08.001
Source: Vaccine - August 6, 2023 Category: Allergy & Immunology Authors: Lindsay R Grant Mary P E Slack Christian Theilacker Jelena Vojicic St éphane Dion Ralf-Rene Reinert Luis Jodar Bradford D Gessner Source Type: research

Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research

Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research

Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.PMID:37507273 | DOI:10.1016/j.vaccine.2023.07.042
Source: Vaccine - July 28, 2023 Category: Allergy & Immunology Authors: Alamgir Kabir Deborah Randall Anthony T Newall Hannah C Moore Sanjay Jayasinghe Parveen Fathima Bette Liu Peter McIntyre Heather F Gidding Source Type: research

Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial
CONCLUSION: Even after PCV10 or PCV13 vaccination, children living in a high-risk setting such as PNG continue to experience high levels of pneumococcal colonization, including carriage of highly antimicrobial-resistant PCV serotypes. The study is registered with ClinicalTrials.gov (CTN NCT01619462).PMID:37479616 | DOI:10.1016/j.vaccine.2023.07.026
Source: Vaccine - July 21, 2023 Category: Allergy & Immunology Authors: Tilda Orami Celestine Aho Rebecca L Ford William S Pomat Andrew Greenhill Lea-Ann Kirkham Geraldine Masiria Birunu Nivio Kathryn J Britton Peter Jacoby Peter C Richmond Anita H J van den Biggelaar Deborah Lehmann Source Type: research

Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60  years in Spain
CONCLUSIONS/RECOMMENDATIONS: In the Spanish adult population older than 60 years, the vaccination strategy with one dose of PCV20 is more effective and less expensive (dominant) than vaccination with a sequential schedule with PCV15 and PPSV23.PMID:37479615 | DOI:10.1016/j.vaccine.2023.07.016
Source: Vaccine - July 21, 2023 Category: Allergy & Immunology Authors: David Cantarero Daniel Oca ña Mar ía Ángeles Onieva-García Juan Rodr íguez-García Paulina G álvez Cristina M éndez Carlos Crespo Alejandra L ópez-Ibáñez de Aldecoa Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20